AC Immune provided an update on positive progress in its active immunotherapy programs, with three Phase 2 trials progressing to key clinical milestones in 2024. ACI-24.060: AC Immune’s wholly-owned anti-amyloid beta active immunotherapy-candidate. The six-month Abeta positron emission tomography imaging results are expected in H1 2024, and the 12-month Abeta PET data are expected in H2 2024. ACI-7104.056: AC Immune’s wholly-owned anti-alpha-synuclein active immunotherapy, to treat Parkinson’s disease. Safety and immunogenicity updates from the trial will be reported in H2 2024. ACI-35.030: AC Immune’s partnered investigational targeted active immunotherapy, selective for pathological phosphorylated Tau. Under the terms of the licensing agreement, AC Immune has received a milestone payment of CHF15 million and expects to receive another milestone payment of CHF 25 million related to achieving an undisclosed enrollment target in 2025.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ACIU:
- AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer’s and Parkinson diseases
- AC Immune Announces Pricing of Underwritten Offering of Common Shares
- AC Immune prices 14.3M shares at $3.50 in underwritten offering
- AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial
- AC Immune reports ACI-35.030 advances into Phase 2b trial